Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124608 | 0.89 | EGFR (0.44) | EGFRERBB2ERBB4BTKMKNK1 | |
| SCHEMBL7117635 | 0.80 | EGFR (0.40) | EGFRERBB2ERBB4KDM4EALDH1A1 | |
| SCHEMBL7120343 | 0.74 | EGFR (0.61) | EGFRERBB2ERBB4BTK | |
| SCHEMBL7117641 | 0.74 | EGFR (0.44) | EGFRERBB2BTKALDH1A1FLT3 | |
| SCHEMBL8524772 | 0.73 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL7117634 | 0.73 | EGFR (0.43) | EGFRERBB2BTKALDH1A1FLT3 | |
| SCHEMBL7125158 | 0.72 | EGFR (0.42) | EGFRERBB2ERBB4BTKMKNK1 | |
| SCHEMBL7125400 | 0.71 | EGFR (0.61) | EGFRERBB2ERBB4 | |
| SCHEMBL7117699 | 0.70 | EGFR (0.45) | EGFRERBB2ERBB4FLT3 | |
| SCHEMBL7120334 | 0.70 | EGFR (0.57) | EGFRERBB2ERBB4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.